Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes

Cancer

Volumn 86, Issue 1, 1999, Pages 72-78

  Symon, Zvi ^a   Peyser, Amos ^a   Tzemach, Dinah ^a   Lyass, Olga ^a   Sucher, Erwin ^a   Shezen, Elias ^a   Gabizon, Alberto ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Bone metastases; Breast carcinoma; Chemotherapy; Doxorubicin; Liposome

Indexed keywords

DOXORUBICIN; LIPOSOME;

ADULT; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CASE REPORT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; LIPOSOMES; TISSUE DISTRIBUTION;

EID: 0033168435     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1     Document Type: Article

References (20)

1. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and anti-tumor therapeutic efficacy. Proc Natl Acad Sci USA 1991;88:11460-4.
2. Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am 1994;8:431-50.
3. Working PK, Dayan AD. Pharmacological-toxicological expert report: CAELYX™ (Stealth® liposomal doxorubicin HCI). Human Exp Toxicol 1996;15:752-85.
4. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumors. Drugs 1997;54(Suppl 4):15-21.
5. Northfelt DW, Dezube BJ, Thammes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-51.
6. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, et al. Liposomal doxorubicin: anti tumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13:1777-85.
7. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15:987-93.
8. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A, et al. Treatment of advanced breast cancer with sterically-stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997;15:3185-91.
9. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor bearing animals. Adv Drug Deliv Rev 1997;17:337-44.
10. Amantea MA, Forrest A, Northfelt DW, Mamelok R. Population pharmacokinetics and pharmacodynamics of pegylated liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 1997;61:301-11.
11. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996;36:55-63.
12. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54: 987-92.
13. Stewart S, Harrington KJ. The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors. Oncology 1997;11(Suppl 11):33-7.
14. Gabizon A, Barenholz, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharmaceutical Res 1993;10:703-8.
15. Huang SK, Lee K-D, Hong K, Friend DS, Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992; 52:5135-43.
16. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 1993;53:3765-70.
17. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994;54:3352-56.
18. Baxter LT, Jain RK. Transport of fluids and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res 1990;40:246-63.
19. Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev 1995;16:285-94.
20. Cummings J, McArdle CS. Studies on the in vivo disposition of adriamycin in human tumors which exhibit different responses to the drug. Br J Cancer 1986;53:835-8.